Deferred Tax Assets, Valuation Allowance of VYNE Therapeutics Inc. from 31 Dec 2015 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
VYNE Therapeutics Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2015 to 31 Dec 2025.
  • VYNE Therapeutics Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $98,683,000, a 2% decline year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

VYNE Therapeutics Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $98,683,000 -$1,996,000 -2% 31 Dec 2025 10-K 27 Feb 2026 2025 FY
Q4 2024 $100,679,000 +$10,906,000 +12% 31 Dec 2024 10-K 27 Feb 2026 2025 FY
Q4 2023 $89,773,000 +$2,900,000 +3.3% 31 Dec 2023 10-K 06 Mar 2025 2024 FY
Q4 2022 $86,873,000 +$1,318,000 +1.5% 31 Dec 2022 10-K 01 Mar 2024 2023 FY
Q4 2021 $85,555,000 +$15,812,000 +23% 31 Dec 2021 10-K 14 Mar 2023 2022 FY
Q4 2020 $69,743,000 -$1,258,000 -1.8% 31 Dec 2020 10-K 17 Mar 2022 2021 FY
Q4 2019 $71,001,000 +$43,406,000 +157% 31 Dec 2019 10-K 04 Mar 2021 2020 FY
Q4 2018 $27,595,000 +$12,602,000 +84% 31 Dec 2018 10-K 03 Mar 2020 2019 FY
Q4 2017 $14,993,000 +$3,362,000 +29% 31 Dec 2017 10-K 03 Mar 2020 2019 FY
Q4 2016 $11,631,000 +$5,010,000 +76% 31 Dec 2016 10-K 28 Feb 2019 2018 FY
Q4 2015 $6,621,000 31 Dec 2015 10-K 28 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.